FDA rais­es safe­ty, ef­fi­ca­cy ques­tions for Fi­bro­Gen's ane­mia drug rox­adu­s­tat with ad­comm on the hori­zon

Ahead of Thurs­day’s meet­ing of the FDA’s Car­dio­vas­cu­lar and Re­nal Drugs Ad­vi­so­ry Com­mit­tee, the agency is rais­ing fresh doubts on whether Fi­bro­Gen’s ane­mia drug rox­adu­s­tat …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER